Navigation Links
MannKind Updates Status of NDA Submission for AFRESA
Date:2/26/2009

VALENCIA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today provided an update on the status of its new drug application ("NDA") for AFRESA(R), an ultra rapid-acting insulin that has completed Phase 3 clinical trials. As previously announced, our internal goal was to submit the NDA to the Food and Drug Administration ("FDA") by the end of February. Based on editorial decisions made during the final stages of preparing the dossier, we have decided to extend the submission date by approximately three weeks.

The document is fully drafted. However, we decided during our final review that it would be preferable to remove several tens of thousands of pages of back-up data from the submission and instead make this material available to the FDA upon request. This change will significantly reduce the size of the NDA and should make the NDA more reviewer-friendly.

"Although I am mindful of our goal to submit the NDA as quickly as possible, it is more important to me that we provide the FDA with a high-quality submission that can be efficiently reviewed," said Dr. Peter Richardson, MannKind's Corporate Vice President and Chief Scientific Officer. "I am not willing to rush the final hyper-linking and quality-checking activities, especially when these efforts could potentially facilitate the FDA's review of our new drug application for AFRESA."

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstre
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MannKind Reports Successful Completion of Device Bioequivalence Trial
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
4. MannKind Addresses Pfizers Announcement Regarding Exubera
5. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
6. AAOMS Updates BRONJ Position Paper
7. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
11. Genmab Announces Updates on Phase III Cancer Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... NEW YORK , May 4, 2015  FireflySci Inc., the newest member of the ... months after launch, they have turned the cuvette industry on its head by offering scientists amazing ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
(Date:5/4/2015)... (PRWEB) May 04, 2015 San ... cutting ceremony at their brand new, 13,700 square foot ... The new building will not only provide fertility treatment ... will also offer community and educational events to a ... facility is located next door to their current Carmel ...
(Date:5/4/2015)... New West Medicare is excited to announce they ... outpatient advanced imaging services for its members. Care to ... are provided the right test at the right time ... West Medicare’s physicians and hospitals, Care to Care will ... and provide an objective basis for informed evidence-based clinical ...
(Date:5/4/2015)... May 04, 2015 Dr. Richard Champagne, ... been chosen to receive the America’s Best Dentist Award, ... Champagne’s selection as a top dentist is a reflection ... continuing education and his compassion for his patients. , ... who exemplify excellence in their field. These nominees are ...
(Date:5/4/2015)... Gettysburg, Pennsylvania (PRWEB) May 04, 2015 ... bicycle and hand cycle ride in the last decade ... after riding 110 miles in two days from the ... national non-profit saw 581 registered disabled and able-bodied participants ... Face of America recognizes and honors the commitment and ...
(Date:5/4/2015)... Food Cost Calculator ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... food costs. , The restaurant industry is a vital cornerstone ... estimated 1.8 trillion dollar impact on the US economy. But ...
Breaking Medicine News(10 mins):Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2
... HALL, N.C., EXTON, Pa. and SAN DIEGO, Nov. ... southeastern US,provider of oncology equipment sales and service, ... alliance with Radiology Oncology Systems, Inc.,(ROS), an oncology ... Acceletronics, Inc., a US provider of oncology equipment ...
... Charged with Illegally Distributing over 12 Million Narcotic ... United States,Attorney Matt M. Dummermuth announced today that ... distribute controlled substances through an,Internet pharmacy and with ... in an Indictment filed today in United States ...
... Calif., Nov. 8 InteKrin Therapeutics, Inc.,a privately-held ... commercialization of novel drugs for the treatment of,diabetes ... M.D. has joined the company as Chief Medical ... senior management team and will be,responsible for the ...
... NEW YORK, Nov. 8 Wolf Popper LLP has ... MDT ) and,certain of its officers and directors ... Minnesota, on behalf of investors who purchased,Medtronic common stock ... 15, 2007 (the "Class Period"). This is the first ...
... (Unaudited) ... For the three months ended For the six months ended ... 2007 2006 ... $3,069,762 $2,315,781 $7,940,405 $7,836,896, Gross profit ...
... for Continued Efforts on $1 Billion ... Life Sciences Legislation Future of Biotechnology Featured: RNA, Nanomedicine, ... 2007 Editor,s Note: Reporters can listening to company presentations at, http://massbio.org/events/mass_opps/press.php ... available on Friday on the ...
Cached Medicine News:Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 2Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 3Health News:Wolf Popper Announces Filing of Securities Class Action Lawsuit Against Medtronic Inc. - MDT 2Health News:Wolf Popper Announces Filing of Securities Class Action Lawsuit Against Medtronic Inc. - MDT 3Health News:MagStar Technologies, Inc. Announces Third Quarter 2007 Results 2Health News:MagStar Technologies, Inc. Announces Third Quarter 2007 Results 3Health News:Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference 2Health News:Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference 3Health News:Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Council's Ninth Annual MASS Opportunities Investment Conference 4
The Olympus full range of laparoscopes includes a range of diameters and directions of view -12 mm HDTV compatible model as well as a choice of 10 mm, 5 mm full screen and 3 mm....
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
Compact, economical Bactron II anaerobic environment system with air lock, workspace and a 200 plate capacity incubator delivers optimum productivity in a compact space....
This chamber is designed to provide a large workspace and gloveless dexterity in closed environment industrial, research and development, quality control packaging applications. Atmospheres of nitrog...
Medicine Products: